These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 32424595)

  • 1. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
    Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
    PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
    Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
    J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
    Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
    Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
    Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
    Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA.
    Shen Y; Wang H; Li W; Chen J
    J Clin Lab Anal; 2019 Nov; 33(9):e22999. PubMed ID: 31418936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
    Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
    Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
    Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
    Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.